$23.49
0.17% yesterday
NYSE, May 30, 10:13 pm CET
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Pfizer Stock News

Neutral
Business Wire
about 14 hours ago
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. T...
Neutral
GlobeNewsWire
one day ago
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer.
Positive
24/7 Wall Street
one day ago
Looking for high-yield dividend stocks below $50? Here are the top five.
Neutral
Business Wire
3 days ago
PENSACOLA, Fla.--(BUSINESS WIRE)--A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States Courthouse is Pensacola, Florida. The litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer's Depo-Provera...
Positive
Seeking Alpha
3 days ago
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Management's focus on non-COVID segments and aggressive cost-cutting initiatives are expected to support margins and EPS growth, trending towards the upper end of FY2025 guidance. Impending LOEs for key d...
Neutral
The Motley Fool
4 days ago
Pfizer (PFE 0.49%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.
Positive
Seeking Alpha
5 days ago
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure ...
Neutral
The Motley Fool
7 days ago
It's been a tough go for Pfizer (PFE 1.28%). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today